Organophosphate intoxication: Molecular consequences, mechanisms and solutions

Handbook of Toxicology of Chemical Warfare Agents

Volumn , Issue , 2009, Pages 691-717

  Geyer, Brian C ^a   Evron, Tama ^b   Soreq, Hermona ^b   Mor, Tsafrir S ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84875809228     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012374484-5.00046-8     Document Type: Chapter

References (308)

1. Aharoni A., Gaidukov L., Yagur S., Toker L., Silman I., Tawfik D.S. Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization. Proc. Natl Acad. Sci. USA 2004, 101:482-487.
2. Akhmedova S., Anisimov S., Yakimovsky A., Schwartz E. Gln/Arg 191 polymorphism of paraoxonase and Parkinson's disease. Hum. Hered. 1999, 49:178-180.
3. Allderdice P.W., Gardner H.A., Galutira D., Lockridge O., LaDu B.N., McAlpine P.J. The cloned butyrylcholinesterase (BCHE) gene maps to a single chromosome site, 3q26. Genomics 1991, 11:452-454.
4. Allon N., Raveh L., Gilat E., Cohen E., Grunwald J., Ashani Y. Prophylaxis against soman inhalation toxicity in guinea pigs by pretreatment alone with human serum butyrylcholinesterase. Toxicol. Sci. 1998, 43:121-128.
5. Andres C., Beeri R., Friedman A., Lev-Lehman E., Henis S., Timberg R., Shani M., Soreq H. Acetylcholinesterase-transgenic mice display embryonic modulations in spinal cord choline acetyltransferase and neurexin Ibeta gene expression followed by late-onset neuromotor deterioration. Proc. Natl Acad. Sci. USA 1997, 94:8173-8178.
6. Andres C., Seidman S., Beeri R., Timberg R., Soreq H. Transgenic acetylcholinesterase induces enlargement of murine neuromuscular junctions but leaves spinal cord synapses intact. Neurochem. Int. 1998, 32:449-456.
7. Anglister L. Acetylcholinesterase from the motor nerve terminal accumulates on the synaptic basal lamina of the myofiber. J. Cell. Biol. 1991, 115:755-764.
8. Anglister L., Haesaert B., McMahan U.J. Globular and asymmetric acetylcholinesterase in the synaptic basal lamina of skeletal muscle. J. Cell. Biol. 1994, 125:183-196.
9. Anglister L., Eichler J., Szabo M., Haesaert B., Salpeter M.M. 125I-labeled fasciculin 2: a new tool for quantitation of acetylcholinesterase densities at synaptic sites by EM-autoradiography. J. Neurosci. Methods 1998, 81:63-71.
10. Appleyard M.E. Secreted acetylcholinesterase: non-classical aspects of a classical enzyme. Trends Neurosci. 1992, 15:485-490.
11. Argov Z., McKee D., Agus S., Brawer S., Shlomowitz N., Ben Yoseph O., Soreq H., Sussman J.D. Treatment of human myasthenia with oral antisense suppression of acetylcholinesterase. Neurology 2007, 69:699-700.
12. Ariel N., Ordentlich A., Barak D., Bino T., Velan B., Shafferman A. The "aromatic patch' of three proximal residues in the human acetylcholinesterase active centre allows for versatile interaction modes with inhibitors. Biochem. J. 1998, 335:95-102.
13. Ashani Y. Prospective of human butyrylcholinesterase as a detoxifying antidote and potential regulator of controlled-release drugs. Drug Dev. Res. 2000, 50:298-308.
14. Ashani Y., Shapira S., Levy D., Wolfe A.D., Doctor B.P., Raveh L. Butyrylcholinesterase and acetylcholinesterase prophylaxis against soman poisoning in mice. Biochem. Pharmacol. 1991, 41:37-41.
15. Atanasova E., Chiappa S., Wieben E., Brimijoin S. Novel messenger RNA and alternative promoter for murine acetylcholinesterase. J. Biol. Chem. 1999, 274:21078-21084.
16. Baldassarre H., Wang B., Keefer C.L., Lazaris A., Karatzas C.N. State of the art in the production of transgenic goats. Reprod. Fertil. Dev. 2004, 16:465-470.
17. Bausero P., Schmitt M., Toussaint J.L., Simoni P., Geoffroy V., Queuche D., Duclaud S., Kempf J., Quirin-Stricker C. Identification and analysis of the human choline acetyltransferase gene promoter. Neuroreport 1993, 4:287-290.
18. Beaman J.R., Finch R., Gardner H., Hoffmann F., Rosencrance A., ZelikoffJ.T. Mammalian immunoassays for predicting the toxicity of malathion in a laboratory fish model. J. Toxicol. Environ. Health A 1999, 56:523-542.
19. Ben-Ari S., Toiber D., Sas A.S., Soreq H., Ben-Shaul Y. Modulated splicing-associated gene expression in P19 cells expressing distinct acetylcholinesterase splice variants. J. Neurochem. 97 (Suppl. 2006, 1):24-34.
20. Ben-Shaul Y., BenMoyal-Segal L., Ben-Ari S., Bergman H., Soreq H. Adaptive acetylcholinesterase splicing patterns attenuate 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice. EJNS 2006, 23:2915-2922.
21. Benmoyal-Segal L., Vander T., Shifman S., Bryk B., Ebstein R.P., Marcus E.L., Stessman J., Darvasi A., Herishanu Y., Friedman A., Soreq H. Acetylcholinesterase/paraoxonase interactions increase the risk of insecticide-induced Parkinson's disease. FASEB J. 2005, 19:452-454.
22. Benning M.M., Kuo J.M., Raushel F.M., Holden H.M. Three-dimensional structure of phosphotriesterase: an enzyme capable of detoxifying organophosphate nerve agents. Biochemistry 1994, 33:15001-15007.
23. Berkowitz G.S., Wetmur J.G., Birman-Deych E., Obel J., Lapinski R.H., Godbold J.H., Holzman I.R., WolffM.S. In utero pesticide exposure, maternal paraoxonase activity, and head circumference. Environ. Health Perspect. 2004, 112:388-391.
24. Berson A., Knobloch M., Diamant S., Sharoni M., Schuppli D., Geyer B., Ravid R., Mor T., Nitsch R., Soreq H. Changes in readthrough acetylcholinesterase expression modulate amyloid-beta pathology. Brain 2008, 131:109-119.
25. Bigbee J.W., Sharma K.V., Chan E.L., Bogler O. Evidence for the direct role of acetylcholinesterase in neurite outgrowth in primary dorsal root ganglion neurons. Brain Res. 2000, 861:354-362.
26. Birikh K.R., Sklan E.H., Shoham S., Soreq H. Interaction of "readthrough' acetylcholinesterase with RACK1 and PKCbeta II correlates with intensified fear-induced conflict behavior. Proc. Natl Acad. Sci. USA 2003, 100:283-288.
27. Bom A., Epemolu O., Hope F., Rutherford S., Thomson K. Selective relaxant binding agents for reversal of neuromuscular blockade. Curr. Opin. Pharmacol. 2007, 7:298-302.
28. Borovikova, L.V., Ivanova, S., Nardi, D., Zhang, M., Yang, H., Ombrellino, M., Tracey, K.J. (2000a). Role of vagus nerve signaling in CNI-1493-mediated suppression of acute inflammation. Auton. Neurosci.85: 141-7.
29. Borovikova, L.V., Ivanova, S., Zhang, M., Yang, H., Botchkina, G.I., Watkins, L.R., Wang, H., Abumrad, N., Eaton, J.W., Tracey, K.J. (2000b). Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature405: 458-62.
30. Brandeis R., Raveh L., Grunwald J., Cohen E., Ashani Y. Prevention of soman-induced cognitive deficits by pretreatment with human butyrylcholinesterase in rats. Pharmacol. Biochem. Behav. 1993, 46:889-896.
31. Brenner T., Hamra-Amitay Y., Evron T., Boneva N., Seidman S., Soreq H. The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis. FASEB J. 2003, 17:214-222.
32. Broomfield C.A., Lockridge O., Millard C.B. Protein engineering of a human enzyme that hydrolyzes V and G nerve agents: design, construction and characterization. Chem. Biol. Interact. 1999, 119-(20):413-418.
33. Brown L.M., Blair A., Gibson R., Everett G.D., Cantor K.P., Schuman L.M., Burmeister L.F., Van Lier S.F., Dick F. Pesticide exposures and other agricultural risk factors for leukemia among men in Iowa and Minnesota. Cancer Res. 1990, 50:6585-6591.
34. Brown M.A., Brix K.A. Review of health consequences from high-, intermediate-and low-level exposure to organophosphorus nerve agents. J. Appl. Toxicol. 1998, 18:393-408.
35. Camp S., De Jaco A., Zhang L., Marquez M., De la Torre B., Taylor P. Acetylcholinesterase expression in muscle is specifically controlled by a promoter-selective enhancesome in the first intron. J. Neurosci. 2008, 28:2459-2470.
36. Caranto G.R., Waibel K.H., Asher J.M., Larrison R.W., Brecht K.M., Schutz M.B., Raveh L., Ashani Y., Wolfe A.D., Maxwell D.M., et al. Amplification of the effectiveness of acetylcholinesterase for detoxification of organophosphorus compounds by bis-quaternary oximes. Biochem. Pharmacol. 1994, 47:347-357.
37. Carlson C.S., Heagerty P.J., Hatsukami T.S., Richter R.J., Ranchalis J., Lewis J., Bacus T.J., McKinstry L.A., Schellenberg G.D., Rieder M., Nickerson D., Furlong C.E., Chait A., Jarvik G.P. TagSNP and haplotype analyses of the paraoxonase gene cluster: effects on PON1 activity, LDL oxidative susceptibility, and carotid artery disease. J. Lipid Res. 2006, 47:1014-1024.
38. Casale G.P., Cohen S.D., DiCapua R.A. The effects of organophosphate-induced cholinergic stimulation on the antibody response to sheep erythrocytes in inbred mice. Toxicol. Appl. Pharmacol. 1983, 68:198-205.
39. Casale G.P., Cohen S.D., DiCapua R.A. Parathion-induced suppression of humoral immunity in inbred mice. Toxicol. Lett. 1984, 23:239-247.
40. Castro C.A., Larsen T., Finger A.V., Solana R.P., McMaster S.B. Behavioral efficacy of diazepam against nerve agent exposure in rhesus monkeys. Pharmacol. Biochem. Behav. 1992, 41:159-164.
41. Cerasoli D.M., Griffiths E.M., Doctor B.P., Saxena A., Fedorko J.M., Greig N.H., Yu Q.S., Huang Y., Wilgus H., Karatzas C.N., Koplovitz I., Lenz D.E. In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger. Chem. Biol. Interact. 2005, 157-8:363-365.
42. Cervini R., Houhou L., Pradat P.F., Bejanin S., Mallet J., Berrard S. Specific vesicular acetylcholine transporter promoters lie within the first intron of the rat choline acetyltransferase gene. J. Biol. Chem. 1995, 270:24654-24657.
43. Chan R.Y., Adatia F.A., Krupa A.M., Jasmin B.J. Increased expression of acetylcholinesterase T and R transcripts during hematopoietic differentiation is accompanied by parallel elevations in the levels of their respective molecular forms. J. Biol. Chem. 1998, 273:9727-9733.
44. Chan R.Y., Boudreau-Lariviere C., Angus L.M., Mankal F.A., Jasmin B.J. An intronic enhancer containing an N-box motif is required for synapse-and tissue-specific expression of the acetylcholinesterase gene in skeletal muscle fibers. Proc. Natl Acad. Sci. USA 1999, 96:4627-4632.
45. Chatonnet A., Lockridge O. Comparison of butyrylcholinesterase and acetylcholinesterase. Biochem. J. 1989, 260:625-634.
46. Cohen O., Erb C., Ginzberg D., Pollak Y., Seidman S., Shoham S., Yirmiya R., Soreq H. Neuronal overexpression of "readthrough' acetylcholinesterase is associated with antisense-suppressible behavioral impairments. Mol. Psychiatry 2002, 7:874-885.
47. Cohen O., Reichenberg A., Perry C., Ginzberg D., Pollmacher T., Soreq H., Yirmiya R. Endotoxin-induced changes in human working and declarative memory associate with cleavage of plasma "readthrough' acetylcholinesterase. J. Mol. Neurosci. 2003, 21:199-212.
48. Conner M.E., Zarley C.D., Hu B., Parsons S., Drabinski D., Greiner S., Smith R., Jiang B., Corsaro B., Barniak V., Madore H.P., Crawford S., Estes M.K. Virus-like particles as a rotavirus subunit vaccine. J. Infect. Dis. 1996, 174:S88-S92.
49. Costa L.G., Cole T.B., Jarvik G.P., Furlong C.E. Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu. Rev. Med. 2003, 54:371-392.
50. Cowan F.M., Broomfield C.A., Stojiljkovic M.P., Smith W.J. A review of multi-threat medical countermeasures against chemical warfare and terrorism. Mil. Med. 2004, 169:850-855.
51. Czura C.J., Tracey K.J. Autonomic neural regulation of immunity. J. Intern. Med. 2005, 257:156-166.
52. D'Amelio M., Ricci I., Sacco R., Liu X., D'Agruma L., Muscarella L.A., Guarnieri V., Militerni R., Bravaccio C., Elia M., Schneider C., Melmed R., Trillo S., Pascucci T., Puglisi-Allegra S., Reichelt K.L., Macciardi F., Holden J.J., Persico A.M. Paraoxonase gene variants are associated with autism in North America, but not in Italy: possible regional specificity in gene-environment interactions. Mol. Psychiatry 2005, 10:1006-1016.
53. Dale, H.H. (1914a). The action of certain esters and ethers of choline, and their relation to muscarine. J. Pharmacol. Exp. Ther.6: 147-90.
54. Dale, H.H. (1914b). The occurrence in ergot and action of acetylcholine. J. Physiol.48 (Suppl.): iii-iv.
55. Dale H.H. Otto Loewi. 1873-1961. Biogr. Mem. Fellows R. Soc. 1962, 8:67-89.
56. Dantoine T.F., Drouet M., Debord J., Merle L., Cogne M., Charmes J.P. Paraoxonase 1 192/55 gene polymorphisms in Alzheimer's disease. Ann. NY Acad. Sci. 2002, 977:239-244.
57. Darreh-Shori T., Hellstrom-Lindahl E., Flores-Flores C., Guan Z.Z., Soreq H., Nordberg A. Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients. J. Neurochem. 2004, 88:1102-1113.
58. De Jaco A., Comoletti D., Kovarik Z., Gaietta G., Radic Z., Lockridge O., Ellisman M.H., Taylor P. A mutation linked with autism reveals a common mechanism of endoplasmic reticulum retention for the α, beta-hydrolase fold protein family. J. Biol. Chem. 2006, 281:9667-9676.
59. Debaene B., Plaud B., Dilly M.P., Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology 2003, 98:1042-1048.
60. Deutsch V.R., Pick M., Perry C., Grisaru D., Hemo Y., Golan-Hadari D., Grant A., Eldor A., Soreq H. The stress-associated acetylcholinesterase variant AChE-R is expressed in human CD34(+) hematopoietic progenitors and its C-terminal peptide ARP promotes their proliferation. Exp. Hematol. 2002, 30:1153-1161.
61. Diamant S., Podoly E., Friedler A., Ligumsky H., Livnah O., Soreq H. Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proc. Natl Acad. Sci. USA 2006, 103:8628-8633.
62. Doctor B.P., Saxena A. Bioscavengers for the protection of humans against organophosphate toxicity. Chem. Biol. Interact. 2005, 157-8:167-171.
63. Donger C., Krejci E., Serradell A.P., Eymard B., Bon S., Nicole S., Chateau D., Gary F., Fardeau M., Massoulie J., Guicheney P. Mutation in the human acetylcholinesterase-associated collagen gene, COLQ, is responsible for congenital myasthenic syndrome with end-late acetylcholinesterase deficiency (type Ic). Am. J. Hum. Genet. 1998, 63:967-975.
64. Dori A., Soreq H. ARP, the cleavable C-terminal peptide of "readthrough' acetylcholinesterase, promotes neuronal development and plasticity. J. Mol. Neurosci. 2006, 28:247-255.
65. Dori A., Cohen J., Silverman W.F., Pollack Y., Soreq H. Functional manipulations of acetylcholinesterase splice variants highlight alternative splicing contributions to murine neocortical development. Cereb. Cortex 2005, 15:419-430.
66. Dori A., Ifergane G., Saar-Levy T., Bersudsky M., Mor I., Soreq H., Wirguin I. Readthrough acetylcholinesterase in inflammation-associated neuropathies. Life Sci. 2007, 80:2369-2374.
67. Drachman D.B. Myasthenia gravis. N. Engl. J. Med. 1994, 330:1797-1810.
68. Dunn M.A., Sidell F.R. Progress in medical defense against nerve agents. JAMA 1989, 262:649-652.
69. Erlich P.M., Lunetta K.L., Cupples L.A., Huyck M., Green R.C., Baldwin C.T., Farrer L.A. Polymorphisms in the PON gene cluster are associated with Alzheimer disease. Hum. Mol. Genet. 2006, 15:77-85.
70. Ehrlich G., Ginzberg D., Loewenstein Y., Glick D., Kerem B., Ben-Ari S., Zakut H., Soreq H. Population diversity and distinct haplotype frequencies associated with ACHE and BCHE genes of Israeli Jews from trans-Caucasian Georgia and from Europe. Genomics 1994, 22:288-295.
71. Ehrlich G., Viegas-Pequignot E., Ginzberg D., Sindel L., Soreq H., Zakut H. Mapping the human acetylcholinesterase gene to chromosome 7q22 by fluorescent in situ hybridization coupled with selective PCR amplification from a somatic hybrid cell panel and chromosome-sorted DNA libraries. Genomics 1992, 13:1192-1197.
72. Ek M., Kurosawa M., Lundeberg T., Ericsson A. Activation of vagal afferents after intravenous injection of interleukin-1beta: role of endogenous prostaglandins. J. Neurosci. 1998, 18:9471-9479.
73. Engelhardt J.I., Siklos L., Appel S.H. Immunization of guinea pigs with human choline acetyltransferase induces selective lower motoneuron destruction. J. Neuroimmunol. 1997, 78:57-68.
74. Ennis M., Aston-Jones G., Shiekhattar R. Activation of locus coeruleus neurons by nucleus paragigantocellularis or noxious sensory stimulation is mediated by intracoerulear excitatory amino acid neurotransmission. Brain Res. 1992, 598:185-195.
75. Erb C., Troost J., Kopf S., Schmitt U., Loffelholz K., Soreq H., Klein J. Compensatory mechanisms enhance hippocampal acetylcholine release in transgenic mice expressing human acetylcholinesterase. J. Neurochem. 2001, 77:638-646.
76. Evron T., Moyal-Segal L.B., Lamm N., Geffen A., Soreq H. RNA-targeted suppression of stress-induced allostasis in primate spinal cord neurons. Neurodegener. Dis. 2005, 2:16-27.
77. Evron, T., Geyer, B.C., Cherni, I., Muralidharan, M., Kilbourne, J., Fletcher, S.P., Soreq, H., Mor, T.S. (2007a). Plant-derived human acetylcholinesterase-R provides protection from lethal organophosphate poisoning and its chronic aftermath. FASEB J.21: 2961-9.
78. Evron, T., Greenberg, D., Mor, T.S., Soreq, H. (2007b). Adaptive changes in acetylcholinesterase gene expression as mediators of recovery from chemical and biological insults. Toxicology233: 97-107.
79. Farchi N., Soreq H., Hochner B. Chronic acetylcholinesterase overexpression induces multilevelled aberrations in mouse neuromuscular physiology. J. Physiol. 2003, 546:165-173.
80. Farchi, N., Ofek, K., Podoly, E., Dong, H., Xiang, Y.Y., Diamant, S., Livnah, O., Li, J., Hochner, B., Lu, W.Y., Soreq, H. (2007a). Peripheral site acetylcholinesterase blockade induces RACK1-associated neuronal remodeling. Neurodegener. Dis.4: 171-84.
81. Farchi, N., Shoham, S., Hochner, B., Soreq, H. (2007b). Impaired hippocampal plasticity and errors in cognitive performance in mice with maladaptive AChE splice site selection. Eur. J. Neurosci.25: 87-98.
82. Feldman, R.G. (1999a). Chapter 22: Organophosphorus compounds. In Occupational and Envronmental Neurotoxicology, pp. 421-41. Lippincott-Raven, Philadelphia.
83. Feldman, R.G. (1999b). Chapter 23: Carbamates. In Occupational and Environmental Neurotoxicology, pp. 442-65. Lippincott-Raven, Philadelphia.
84. Fischer R., Emans N. Molecular farming of pharmaceutical proteins. Transgenic Res. 2000, 9:279-299.
85. Fisher A. Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists. Jpn. J. Pharmacol. 2000, 84:101-112.
86. Fletcher S.P., Geyer B.C., Smith A., Evron T., Joshi L., Soreq H., Mor T.S. Tissue distribution of cholinesterases and anticholinesterases in native and transgenic tomato plants. Plant Mol. Biol. 2004, 55:33-43.
87. Fox M.A., Umemori H. Seeking long-term relationship: axon and target communicate to organize synaptic differentiation. J. Neurochem. 2006, 97:1215-1231.
88. Friedman A., Kaufer D., Shemer J., Hendler I., Soreq H., Tur-Kaspa I. Pyridostigmine brain penetration under stress enhances neuronal excitability and induces early immediate transcriptional response. Nat. Med. 1996, 2:1382-1385.
89. Furlong C.E., Li W.F., Richter R.J., Shih D.M., Lusis A.J., Alleva E., Costa L.G. Genetic and temporal determinants of pesticide sensitivity: role of paraoxonase (PON1). Neurotoxicology 2000, 21:91-100.
90. Furlong C.E., Cole T.B., Jarvik G.P., Pettan-Brewer C., Geiss G.K., Richter R.J., Shih D.M., Tward A.D., Lusis A.J., Costa L.G. Role of paraoxonase (PON1) status in pesticide sensitivity: genetic and temporal determinants. Neurotoxicology 2005, 26:651-659.
91. Furlong C.E., Holland N., Richter R.J., Bradman A., Ho A., Eskenazi B. PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. Pharmacogenet. Genomics 2006, 16:183-190.
92. Gallowitsch-Puerta M., Tracey K.J. Immunologic role of the cholinergic anti-inflammatory pathway and the nicotinic acetylcholine alpha 7 receptor. Ann. NY Acad. Sci. 2005, 1062:209-219.
93. Galyam N., Grisaru D., Grifman M., Melamed-Book N., Eckstein F., Seidman S., Eldor A., Soreq H. Complex host cell responses to antisense suppression of ACHE gene expression. Antisense Nucl. Acid Drug Dev. 2001, 11:51-57.
94. Genovese R.F., Doctor B.P. Behavioral and pharmacological assessment of butyrylcholinesterase in rats. Pharmacol. Biochem. Behav. 1995, 51:647-654.
95. Geyer B.C., Muralidharan M., Cherni I., Doran J., Fletcher S.P., Evron T., Soreq H., Mor T.S. Purification of transgenic plant-derived recombinant human acetylcholinesterase-R. Chem. Biol. Interact. 2005, 157-8:331-334.
96. Geyer B.C., Fletcher S.P., Griffin T.A., Lopker M.J., Soreq H., Mor T.S. Translational control of recombinant human acetylcholinesterase accumulation in plants. BMC Biotechnol. 2007, 7:27.
97. Giacobini E. Invited review: cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications. Neurochem. Int. 1998, 32:413-419.
98. Gilboa-Geffen A., Lacoste P.P., Soreq L., Cizeron-Clairac G., Le Panse R., Truffault F., Shaked I., Soreq H., Berrih-Aknin S. The thymic theme of acetylcholinesterase splice variants in myasthenia gravis. Blood 2007, 109:4383-4391.
99. Gopal S., Rastogi V., Ashman W., Mulbry W. Mutagenesis of organophosphorus hydrolase to enhance hydrolysis of the nerve agent VX. Biochem. Biophys. Res. Commun 2000, 279:516-519.
100. Greenfield S. Acetylcholinesterase may have novel functions in the brain. Trends Neurosci. 1984, 7:364-368.
101. Greenfield S. Non-classical actions of cholinesterases: role in cellular differentiation, tumorigenesis and Alzheimer's disease. Neurochem. Int. 1996, 28:485-490.
102. Greenfield S., Vaux D.J. Parkinson's disease, Alzheimer's disease and motor neurone disease: identifying a common mechanism. Neuroscience 2002, 113:485-492.
103. Grifman M., Soreq H. Differentiation intensifies the susceptibility of pheochromocytoma cells to antisense oligodeoxynucleotide-dependent suppression of acetylcholinesterase activity. Antisense Nucl. Acid Drug Dev. 1997, 7:351-359.
104. Grifman M., Galyam N., Seidman S., Soreq H. Functional redundancy of acetylcholinesterase and neuroligin in mammalian neuritogenesis [in process citation]. Proc. Natl Acad. Sci. USA 1998, 95:13935-13940.
105. Grimsley J.K., Calamini B., Wild J.R., Mesecar A.D. Structural and mutational studies of organophosphorus hydrolase reveal a cryptic and functional allosteric-binding site. Arch. Biochem. Biophys. 2005, 442:169-179.
106. Grisaru, D., Lev-Lehman, E., Shapira, M., Chaikin, E., Lessing, J.B., Eldor, A., Eckstein, F., Soreq, H. (1999a). Human osteogenesis involves differentiation-dependent increases in the morphogenically active 30 alternative splicing variant of acetylcholinesterase. Mol. Cell. Biol.19: 788-95.
107. Grisaru, D., Sternfeld, M., Eldor, A., Glick, D., Soreq, H. (1999b). Structural roles of acetylcholinesterase variants in biology and pathology. Eur. J. Biochem.264: 672-86.
108. Grisaru D., Deutsch V., Shapira M., Pick M., Sternfeld M., Melamed-Book N., Kaufer D., Galyam N., Gait M.J., Owen D., Lessing J.B., Eldor A., Soreq H. ARP, a peptide derived from the stress-associated acetylcholinesterase variant, has hematopoietic growth promoting activities. Mol. Med. 2001, 7:93-105.
109. Grisaru D., Pick M., Perry C., Sklan E.H., Almog R., Goldberg I., Naparstek E., Lessing J.B., Soreq H., Deutsch V. Hydrolytic and nonenzymatic functions of acetylcholinesterase comodulate hemopoietic stress responses. J. Immunol. 2006, 176:27-35.
110. Grunwald J., Marcus D., Papier Y., Raveh L., Pittel Z., Ashani Y. Large-scale purification and long-term stability of human butyrylcholinesterase: a potential bioscavenger drug. J. Biochem. Biophys. Methods 1997, 34:123-135.
111. Gunderson C.H., Lehmann C.R., Sidell F.R., Jabbari B. Nerve agents: a review. Neurology 1992, 42:946-950.
112. Gupta R.C. Classification and uses of organophosphates and carbamates. Toxicology of Organophosphates and Carbamate Compounds 2006, 5-24. Academic Press/Elsevier, Amsterdam. R.C. Gupta (Ed.).
113. Haley R.W., Billecke S., La Du B.N. Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans. Toxicol. Appl. Pharmacol. 1999, 157:227-233.
114. Hall L.M., Spierer P. The Ace locus of Drosophila melanogaster: structural gene for acetylcholinesterase with an unusual 50 leader. EMBO J. 1986, 5:2949-2954.
115. Harel M., Aharoni A., Gaidukov L., Brumshtein B., Khersonsky O., Meged R., Dvir H., Ravelli R.B., McCarthy A., Toker L., Silman I., Sussman J.L., Tawfik D.S. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat. Struct. Mol. Biol. 2004, 11:412-419.
116. Harlow M.L., Ress D., Stoschek A., Marshall R.M., McMahan U.J. The architecture of active zone material at the frog's neuromuscular junction. Nature 2001, 409:479-484.
117. Hartleib J., Ruterjans H. High-yield expression, purification, and characterization of the recombinant diisopropylfluorophosphatase from. Loligo vulgaris. Protein Expr. Purif. 2001, 21:210-219.
118. Haviv H., Wong D.M., Silman I., Sussman J.L. Bivalent ligands derived from Huperzine A as acetylcholinesterase inhibitors. Curr. Top. Med. Chem. 2007, 7:375-387.
119. Heaton K.J., Palumbo C.L., Proctor S.P., Killiany R.J., Yurgelun-Todd D.A., White R.F. Quantitative magnetic resonance brain imaging in US army veterans of the 1991 Gulf War potentially exposed to sarin and cyclosarin. Neurotoxicology 2007, 28:761-769.
120. Hellstrom-Lindahl E., Gorbounova O., Seiger A., Mousavi M., Nordberg A. Regional distribution of nicotinic receptors during prenatal development of human brain and spinal cord. Brain Res. Dev. Brain Res. 1998, 108:147-160.
121. HerkenhoffS., Szinicz L., Rastogi V.K., Cheng T.C., DeFrank J.J., Worek F. Effect of organophosphorus hydrolysing enzymes on obidoxime-induced reactivation of organophosphate-inhibited human acetylcholinesterase. Arch. Toxicol. 2004, 78:338-343.
122. Huang Y.J., Huang Y., Baldassarre H., Wang B., Lazaris A., Leduc M., Bilodeau A.S., Bellemare A., Cote M., Herskovits P., Touati M., Turcotte C., Valeanu L., Lemee N., Wilgus H., Begin I., Bhatia B., Rao K., Neveu N., Brochu E., Pierson J., Hockley D.K., Cerasoli D.M., Lenz D.E., Karatzas C.N., Langermann S. Recombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoning. Proc. Natl Acad. Sci. USA 2007, 104:13603-13608.
123. Hund E. Myopathy in critically ill patients. Crit. Care Med. 1999, 27:2544-2547.
124. Hund, E. (2001a). Critical illness polyneuropathy. Curr. Opin. Neurol.14: 649-53.
125. Hund, E. (2001b). Neurological complications of sepsis: critical illness polyneuropathy and myopathy. J. Neurol.248: 929-34.
126. Huston J.M., Ochani M., Rosas-Ballina M., Liao H., Ochani K., Pavlov V.A., Gallowitsch-Puerta M., Ashok M., Czura C.J., Foxwell B., Tracey K.J., Ulloa L. Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis. J. Exp. Med. 2006, 203:1623-1628.
127. Imperato A., Puglisi-Allegra S., Casolini P., Angelucci L. Changes in brain dopamine and acetylcholine release during and following stress are independent of the pituitary-adrenocortical axis. Brain Res. 1991, 538:111-117.
128. Inestrosa N.C., Alvarez A., Perez C.A., Moreno R.D., Vicente M., Linker C., Casanueva O.I., Soto C., Garrido J. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 1996, 16:881-891.
129. Jaeger L.B., Banks W.A. Antisense therapeutics and the treatment of CNS disease. Front. Biosci. 2004, 9:1720-1727.
130. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J. Biol. Chem. 2000, 275:3957-3962.
131. Janka Z., Juhasz A., Rimanoczy A.A., Boda K., Marki-Zay J., Kalman J. Codon 311 (Cys/Ser) polymorphism of paraoxonase-2 gene is associated with apolipoprotein E4 allele in both Alzheimer's and vascular dementias. Mol. Psychiatry 2002, 7:110-112.
132. Jasmin B.J., Lee R.K., Rotundo R.L. Compartmentalization of acetylcholinesterase mRNA and enzyme at the vertebrate neuromuscular junction. Neuron 1993, 11:467-477.
133. Johnson G., Moore S.W. Human acetylcholinesterase binds to mouse laminin-1 and human collagen IV by an electrostatic mechanism at the peripheral anionic site. Neurosci. Lett. 2003, 337:37-40.
134. Johnson G., Moore S.W. Identification of a structural site on acetylcholinesterase that promotes neurite outgrowth and binds laminin-1 and collagen IV. Biochem. Biophys. Res. Commun. 2004, 319:448-455.
135. Johnson G., Moore S.W. Acetylcholinesterase readthrough peptide shares sequence similarity to the 28-53 peptide sequence of the acetylcholinesterase adhesion-mediating site and competes for ligand binding in vitro. J. Mol. Neurosci. 2007, 31:113-126.
136. Johnson G.N., Rutherford A.W., Krieger A. A change in the midpoint potential of the quinone Q-A in photosystem associated with photoactivation of oxygen evolution. Biochim. Biophys. Acta 1995, 1229:202-207.
137. Josse, D., Xie, W., Masson, P., Lockridge, O. (1999a). Human serum paraoxonase (PON1): identification of essential amino acid residues by group-selective labelling and site-directed mutagenesis. Chem. Biol. Interact.119-20: 71-8.
138. Josse, D., Xie, W., Masson, P., Schopfer, L.M., Lockridge, O. (1999b). Tryptophan residue(s) as major components of the human serum paraoxonase active site. Chem. Biol. Interact.119-20: 79-84.
139. Josse D., Xie W., Renault F., Rochu D., Schopfer L.M., Masson P., Lockridge O. Identification of residues essential for human paraoxonase (PON1) arylesterase/organophosphatase activities. Biochemistry 1999, 38:2816-2825.
140. Josse D., Lockridge O., Xie W., Bartels C.F., Schopfer L.M., Masson P. The active site of human paraoxonase (PON1). J. Appl. Toxicol. 21 (Suppl. 2001, 1):S7-S11.
141. Kaliste-Korhonen E., Tuovinen K., Hanninen O. Interspecies differences in enzymes reacting with organophosphates and their inhibition by paraoxon in vitro. Hum. Exp. Toxicol. 1996, 15:972-978.
142. Kaplan D., Ordentlich A., Barak D., Ariel N., Kronman C., Velan B., Shafferman A. Does "butyrylization' of acetylcholinesterase through substitution of the six divergent aromatic amino acids in the active center gorge generate an enzyme mimic of butyrylcholinesterase?. Biochemistry 2001, 40:7433-7445.
143. Katz E.J., Cortes V.I., Eldefrawi M.E., Eldefrawi A.T. Chlorpyrifos, parathion, and their oxons bind to and desensitize a nicotinic acetylcholine receptor: relevance to their toxicities. Toxicol. Appl. Pharmacol. 1997, 146:227-236.
144. Kaufer D., Soreq H. Tracking cholinergic pathways from psychological and chemical stressors to variable neurodeterioration paradigms. Curr. Opin. Neurol. 1999, 12:739-743.
145. Kaufer D., Friedman A., Seidman S., Soreq H. Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature 1998, 393:373-377.
146. Kawabuchi M., Osame M., Watanabe S., Igata A., Kanaseki T. Myopathic changes at the end-plate region induced by neostigmine methylsulfate. Experientia 1976, 32:632-635.
147. Kehat R., Zemel E., Cuenca N., Evron T., Toiber D., Loewenstein A., Soreq H., Perlman I. A novel isoform of acetylcholinesterase exacerbates photoreceptor death after photic stress. Invest. Ophthalmol. Vis. Sci. 2007, 48:1290-1297.
148. Khersonsky O., Tawfik D.S. The histidine 115-histidine 134 dyad mediates the lactonase activity of mammalian serum paraoxonases. J. Biol. Chem. 2006, 281:7649-7656.
149. Kolarich D., Weber A., Pabst M., Stadlmann J., Teschner W., Ehrlich H., Schwarz H.P., Altmann F. Glycoproteomic characterization of butyrylcholinesterase from human plasma. Proteomics 2008, 8:254-263.
150. Kondo I., Yamamoto M. Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson's disease. Brain Res. 1998, 806:271-273.
151. Kramer A. The structure and function of proteins involved in mammalian pre-mRNA splicing. Annu. Rev. Biochem. 1996, 65:367-409.
152. Krejci, E., Martinez-Pena y Valenzuela, I., Ameziane, R., Akaaboune, M. (2006). Acetylcholinesterase dynamics at the neuromuscular junction of live animals. J. Biol. Chem.281: 10347-54.
153. Kronman C., Velan B., Gozes Y., Leitner M., Flashner Y., Lazar A., Marcus D., Sery T., Papier Y., Grosfeld H., Cohen S., Shafferman A. Production and secretion of high levels of recombinant human acetylcholinesterase in cultured cell lines: microheterogeneity of the catalytic subunit. Gene 1992, 121:295-304.
154. Kronman C., Chitlaru T., Elhanany E., Velan B., Shafferman A. Hierarchy of post-translational modifications involved in the circulatory longevity of glycoproteins. Demonstration of concerted contributions of glycan sialylation and subunit assembly to the pharmacokinetic behavior of bovine acetylcholinesterase. J. Biol. Chem. 2000, 275:29488-29502.
155. Kryger G., Harel M., Giles K., Toker L., Velan B., Lazar A., Kronman C., Barak D., Ariel N., Shafferman A., Silman I., Sussman J.L. Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II. Acta Crystallogr. D Biol. Crystallogr. 56. Pt 2000, 11):1385-1394.
156. La Du B.N., Aviram M., Billecke S., Navab M., Primo-Parmo S., Sorenson R.C., Standiford T.J. On the physiological role(s) of the paraoxonases. Chem. Biol. Interact. 1999, 119-20:379-388.
157. Laskowski M.B., Olson W.H., Dettbarn W.D. Ultrastructural changes at the motor end-plant produced by an irreversible cholinesterase inhibitor. Exp. Neurol. 1975, 47:290-306.
158. Layer P.G. Non-classical actions of cholinesterases: role in cellular differentiation, tumorigenesis and Alzheimer's disease. Neurochem. Int. 1996, 28:491-495.
159. Layer P.G., Weikert T., Alber R. Cholinesterases regulate neurite growth of chick nerve cells in vitro by means of a non-enzymatic mechanism. Cell Tissue Res. 1993, 273:219-226.
160. Leadbeater L., Inns R.H., Rylands J.M. Treatment of poisoning by soman. Fundam. Appl. Toxicol. 1985, 5:S225-S231.
161. Lee E.C. Clinical manifestations of sarin nerve gas exposure. JAMA 2003, 290:659-662.
162. Lenz D.E., Maxwell D.M., Koplovitz I., Clark C.R., Capacio B.R., Cerasoli D.M., Federko J.M., Luo C., Saxena A., Doctor B.P., Olson C. Protection against soman or VX poisoning by human butyrylcholinesterase in guinea pigs and cynomolgus monkeys. Chem. Biol. Interact. 2005, 157-8:205-210.
163. Lev-Lehman E., Evron T., Broide R.S., Meshorer E., Ariel I., Seidman S., Soreq H. Synaptogenesis and myopathy under acetylcholinesterase overexpression. J. Mol. Neurosci. 2000, 14:93-105.
164. Li B., Sedlacek M., Manoharan I., Boopathy R., Duysen E.G., Masson P., Lockridge O. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem. Pharmacol. 2005, 70:1673-1684.
165. Li B., Duysen E.G., Carlson M., Lockridge O. The butyrylcholinesterase knockout mouse as a model for human butyrylcholinesterase deficiency. J. Pharmacol. Exp. Ther. 2008, 324:1146-1154.
166. Li W.F., Costa L.G., Richter R.J., Hagen T., Shih D.M., Tward A., Lusis A.J., Furlong C.E. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 2000, 10:767-779.
167. Li Y., Camp S., Rachinsky T.L., Getman D., Taylor P. Gene structure of mammalian acetylcholinesterase. Alternative exons dictate tissue-specific expression. J. Biol. Chem. 1991, 266:23083-23090.
168. Li Y., Camp S., Taylor P. Tissue-specific expression and alternative mRNA processing of the mammalian acetylcholinesterase gene. J. Biol. Chem. 1993, 268:5790-5797.
169. Li, Y., King, M.A., Meyer, E.M. (2000a). Alpha7 nicotinic receptor-mediated protection against ethanol-induced oxidative stress and cytotoxicity in PC12 cells. Brain Res.861: 165-7.
170. Li, Y., Liu, L., Kang, J., Sheng, J.G., Barger, S.W., Mrak, R.E., Griffin, W.S. (2000b). Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression. J. Neurosci.20: 149-55.
171. Lin C.L., Bristol L.A., Jin L., Dykes-Hoberg M., Crawford T., Clawson L., Rothstein J.D. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 1998, 20:589-602.
172. Lindstrom J. Mutations causing muscle weakness. Proc. Natl Acad. Sci. USA 1998, 95:9070-9071.
173. Livneh A., Sarova I., Michaeli D., Pras M., Wagner K., Zakut H., Soreq H. Antibodies against acetylcholinesterase and low levels of cholinesterases in a patient with an atypical neuromuscular disorder. Clin. Immunol. Immunopathol. 1988, 48:119-131.
174. Lockridge O., Blong R.M., Masson P., Froment M.T., Millard C.B., Broomfield C.A. A single amino acid substitution, Gly117His, confers phosphotriesterase (organophosphorus acid anhydride hydrolase) activity on human butyrylcholinesterase. Biochemistry 1997, 36:786-795.
175. Loewenstein Y., Gnatt A., Neville L.F., Soreq H. Chimeric human cholinesterase. Identification of interaction sites responsible for recognition of acetyl-or butyrylcholinesterase-specific ligands. J. Mol. Biol. 1993, 234:289-296.
176. Loewi O., Navratil E. Über humorale Uebertragbarkeit der Herznervenwirkung XI Mitteilung. Über den Mechanismus der Vaguswirkung von Physostigmin und Ergotamin. Pflu. Arch. Physiol. 1926, 214:689-696.
177. Lusis A.J. Atherosclerosis. Nature 2000, 407:233-241.
178. Mack A., Robitzki A. The key role of butyrylcholinesterase during neurogenesis and neural disorders: an antisense-50butyrylcholinesterase-DNA study. Prog. Neurobiol. 2000, 60:607-628.
179. Mackness, B., Durrington, P.N., Mackness, M.I. (1998a). Human serum paraoxonase. Gen. Pharmacol.31: 329-36.
180. Mackness, M.I., Mackness, B., Durrington, P.N., Fogelman, A.M., Berliner, J., Lusis, A.J., Navab, M., Shih, D., Fonarow, G.C. (1998b). Paraoxonase and coronary heart disease. Curr. Opin. Lipidol.9: 319-24.
181. Marrs T.C. Organophosphate poisoning. Pharmacol. Ther. 1993, 58:51-66.
182. Mason H.S., Warzecha H., Mor T., Arntzen C.J. Edible plant vaccines: applications for prophylactic and therapeutic molecular medicine. Trends Mol. Med. 2002, 8:324-329.
183. Masson P., Josse D., Lockridge O., Viguie N., Taupin C., Buhler C. Enzymes hydrolyzing organophosphates as potential catalytic scavengers against organophosphate poisoning. J. Physiol. Paris 1998, 92:357-362.
184. Massoulie J. The origin of the molecular diversity and functional anchoring of cholinesterases. Neurosignals 2002, 11:130-143.
185. Massoulie J., Pezzementi L., Bon S., Krejci E., Vallette F.M. Molecular and cellular biology of cholinesterases. Prog. Neurobiol. 1993, 41:31-91.
186. Masuda J., Mitsushima D., Kimura F. Female rats living in small cages respond to restraint stress with both adrenocortical corticosterone release and acetylcholine release in the hippocampus. Neurosci. Lett. 2004, 358:169-172.
187. Maxwell D.M., Castro C.A., De La Hoz D.M., Gentry M.K., Gold M.B., Solana R.P., Wolfe A.D., Doctor B.P. Protection of rhesus monkeys against soman and prevention of performance decrement by pretreatment with acetylcholinesterase. Toxicol. Appl. Pharmacol. 1992, 115:44-49.
188. Maxwell D.M., Brecht K.M., Doctor B.P., Wolfe A.D. Comparison of antidote protection against soman by pyridostigmine, HI-6 and acetylcholinesterase. J. Pharmacol. Exp. Ther. 1993, 264:1085-1089.
189. Maxwell D.M., Saxena A., Gordon R.K., Doctor B.P. Improvements in scavenger protection against organophosphorus agents by modification of cholinesterases. Chem. Biol. Interact. 1999, 119-20:419-428.
190. McEwen B.S. Stress and hippocampal plasticity. Annu. Rev. Neurosci. 1999, 22:105-122.
191. McTiernan C., Adkins S., Chatonnet A., Vaughan T.A., Bartels C.F., Kott M., Rosenberry T.L., La Du B.N., Lockridge O. Brain cDNA clone for human cholinesterase. Proc. Natl Acad. Sci. USA 1987, 84:6682-6686.
192. Meshorer E., Soreq H. Pre-mRNA splicing modulations in senescence. Aging Cell 2002, 1:10-16.
193. Meshorer E., Soreq H. Virtues and woes of AChE alternative splicing in stress-related neuropathologies. Trends Neurosci. 2006, 29:216-224.
194. Meshorer E., Erb C., Gazit R., Pavlovsky L., Kaufer D., Friedman A., Glick D., Ben-Arie N., Soreq H. Alternative splicing and neuritic mRNA translocation under long-term neuronal hypersensitivity. Science 2002, 295:508-512.
195. Meshorer E., Toiber D., Zurel D., Sahly I., Dori A., Cagnano E., Schreiber L., Grisaru D., Tronche F., Soreq H. Combinatorial complexity of 50 alternative acetylcholinesterase transcripts and protein products. J. Biol. Chem. 2004, 279:29740-29751.
196. Meshorer, E., Biton, I.E., Ben-Shaul, Y., Ben-Ari, S., Assaf, Y., Soreq, H., Cohen, Y. (2005a). Chronic cholinergic imbalances promote brain diffusion and transport abnormalities. FASEB J.19: 910-22.
197. Meshorer, E., Bryk, B., Toiber, D., Cohen, J., Podoly, E., Dori, A., Soreq, H. (2005b). SC35 promotes sustainable stress-induced alternative splicing of neuronal acetylcholinesterase mRNA. Mol. Psychiatry10: 985-97.
198. Mezey G., Robbins I. Usefulness and validity of post-traumatic stress disorder as a psychiatric category. BMJ 2001, 323:561-563.
199. Millard C.B., Broomfield C.A. Anticholinesterases: medical applications of neurochemical principles. J. Neurochem. 1995, 64:1909-1918.
200. Millard C.B., Lockridge O., Broomfield C.A. Design and expression of organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase. Biochemistry 1995, 34:15925-15933.
201. Millard C.B., Lockridge O., Broomfield C.A. Organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase: synergy results in a somanase. Biochemistry 1998, 37:237-247.
202. Mochizuki H., Scherer S.W., Xi T., Nickle D.C., Majer M., Huizenga J.J., Tsui L.C., Prochazka M. Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene 1998, 213:149-157.
203. Mor, I., Grisaru, D., Titelbaum, L., Evron, T., Richler, C., Wahrman, J., Sternfeld, M., Yogev, L., Meiri, N., Seidman, S., Soreq, H. (2001a). Modified testicular expression of stress-associated "readthrough" acetylcholinesterase predicts male infertility. FASEB J.15: 2039-41.
204. Mor, T.S., Sternfeld, M., Soreq, H., Arntzen, C.J., Mason, H.S. (2001b). Expression of recombinant human acetylcholinesterase in transgenic tomato plants. Biotechnol. Bioeng.75: 259-66.
205. Mor T.S., Soreq H. Human cholinesterases from plants for detoxification. Encyclopedia of Plant and Crop Science 2004, 564-567. Marcel Dekker, New York. R.M. Goodman (Ed.).
206. Mor I., Sklan E.H., Podoly E., Pick M., Kirschner M., Yogev L., Bar-Sheshet Itach S., Schreiber L., Geyer B., Mor T., Grisaru D., Soreq H. Acetylcholinesterase-R increases germ cell apoptosis but enhances sperm motility. J. Cell. Mol. Med. 2008, 12:479-495.
207. Moral-Naranjo M.T., Cabezas-Herrera J., Campoy F.J., Vidal C.J. Differential glycosylation of asymmetric acetylcholinesterase forms in external and internal muscle membranes. Biochem. Soc. Trans. 1997, 25:441S.
208. Mukherjee P.K., Kumar V., Mal M., Houghton P.J. Acetylcholinesterase inhibitors from plants. Phytomedicine 2007, 14:289-300.
209. Newmark J. pathophysiology and treatment of poisoning. Semin. Neurol. 2004, 24:185-196. Nerve agents.
210. Ngamelue M.N., Homma K., Lockridge O., Asojo O.A. Crystallization and X-ray structure of full-length recombinant human butyrylcholinesterase. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 2007, 63:723-727.
211. Nicolet Y., Lockridge O., Masson P., Fontecilla-Camps J.C., Nachon F. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J. Biol. Chem. 2003, 278:41141-41147.
212. Nijholt I., Farchi N., Kye M., Sklan E.H., Shoham S., Verbeure B., Owen D., Hochner B., Spiess J., Soreq H., Blank T. Stress-induced alternative splicing of acetylcholinesterase results in enhanced fear memory and long-term potentiation. Mol. Psychiatry 2004, 9:174-183.
213. Nissim-Rafinia M., Kerem B. The splicing machinery is a genetic modifier of disease severity. Trends Genet. 2005, 21:480-483.
214. Nizri E., Hamra-Amitay Y., Sicsic C., Lavon I., Brenner T. Anti-inflammatory properties of cholinergic up-regulation: a new role for acetylcholinesterase inhibitors. Neuropharmacology 2006, 50:540-547.
215. Nozaki H., Hori S., Shinozawa Y., Fujishima S., Takuma K., Kimura H., Suzuki M., Aikawa N. Relationship between pupil size and acetylcholinesterase activity in patients exposed to sarin vapor. Intensive Care Med. 1997, 23:1005-1007.
216. Ofek K., Krabbe K.S., Evron T., Debecco M., Nielsen A.R., Brunnsgaad H., Yirmiya R., Soreq H., Pedersen B.K. Cholinergic status modulations in human volunteers under acute inflammation. J. Mol. Med. 2007, 85:1239-1251.
217. Ohno K., Engel A.G., Brengman J.M., Shen X.M., Heidenreich F., Vincent A., Milone M., Tan E., Demirci M., Walsh P., Nakano S., Akiguchi I. The spectrum of mutations causing end-plate acetylcholinesterase deficiency. Ann. Neurol. 2000, 47:162-170.
218. Oke S.L., Tracey K.J. From CNI-1493 to the immunological homunculus: physiology of the inflammatory reflex. J. Leukoc. Biol. 2008, 83:512-517.
219. Paraoanu L.E., Layer P.G. Mouse acetylcholinesterase interacts in yeast with the extracellular matrix component laminin-1beta. FEBS Lett. 2004, 576:161-164.
220. Pasca S.P., Nemes B., Vlase L., Gagyi C.E., Dronca E., Miu A.C., Dronca M. High levels of homocysteine and low serum paraoxonase 1 arylesterase activity in children with autism. Life Sci. 2006, 78:2244-2248.
221. Pavlov V.A., Wang H., Czura C.J., Friedman S.G., Tracey K.J. The cholinergic anti-inflammatory pathway: a missing link in neuroimmunomodulation. Mol. Med. 2003, 9:125-134.
222. Pena-Philippides J.C., Razani-Boroujerdi S., Singh S.P., Langley R.J., Mishra N.C., Henderson R.F., Sopori M.L. Long-and short-term changes in the neuroimmune-endocrine parameters following inhalation exposures of F344 rats to low-dose sarin. Toxicol. Sci. 2007, 97:181-188.
223. Perrier A.L., Massoulie J., Krejci E. PRiMA: the membrane anchor of acetylcholinesterase in the brain. Neuron 2002, 33:275-285.
224. Perrier N.A., Salani M., Falasca C., Bon S., Augusti-Tocco G., Massoulie J. The readthrough variant of acetylcholinesterase remains very minor after heat shock, organophosphate inhibition and stress, in cell culture and in vivo. J. Neurochem. 2005, 94:629-638.
225. Perry C., Soreq H. Organophosphate risk of leukemogenesis. Leuk. Res. 2004, 28:905-906.
226. Perry C., Sklan E.H., Soreq H. CREB regulates AChE-R-induced proliferation of human glioblastoma cells. Neoplasia 2004, 6:279-286.
227. Perry C., Pick M., Podoly E., Gilboa-Geffen A., Zimmerman G., Sklan E.H., Ben-Shaul Y., Diamant S., Soreq H. Acetylcholinesterase/C terminal binding protein interactions modify Ikaros functions, causing T lymphopenia. Leukemia 2007, 21:1472-1480.
228. Perry E.K., Lee M.L., Martin-Ruiz C.M., Court J.A., Volsen S.G., Merrit J., Folly E., Iversen P.E., Bauman M.L., Perry R.H., Wenk G.L. Cholinergic activity in autism: abnormalities in the cerebral cortex and basal forebrain. Am. J. Psychiatry 2001, 158:1058-1066.
229. Pick M., Flores-Flores C., Soreq H. From brain to blood: alternative splicing evidence for the cholinergic basis of mammalian stress responses. Ann. NY Acad. Sci. 2004, 1018:85-98.
230. Pick M., Perry C., Lapidot T., Guimaraes-Sternberg C., Naparstek E., Deutsch V., Soreq H. Stress-induced cholinergic signaling promotes inflammation-associated thrombopoiesis. Blood 2006, 107:3397-3406.
231. Pitossi F., del Rey A., Kabiersch A., Besedovsky H. Induction of cytokine transcripts in the central nervous system and pituitary following peripheral administration of endotoxin to mice. J. Neurosci. Res. 1997, 48:287-298.
232. Pola R., Flex A., Ciaburri M., Rovella E., Valiani A., Reali G., Silveri M.C., Bernabei R. Responsiveness to cholinesterase inhibitors in Alzheimer's disease: a possible role for the 192 Q/R polymorphism of the PON-1 gene. Neurosci. Lett. 2005, 382:338-341.
233. Pollak Y., Gilboa A., Ben-Menachem O., Ben-Hur T., Soreq H., Yirmiya R. Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production. Ann. Neurol. 2005, 57:741-745.
234. Primo-Parmo S.L., Sorenson R.C., Teiber J., La Du B.N. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996, 33:498-507.
235. Prody C.A., Zevin-Sonkin D., Gnatt A., Goldberg O., Soreq H. Isolation and characterization of full-length cDNA clones coding for cholinesterase from fetal human tissues. Proc. Natl Acad. Sci. USA 1987, 84:3555-3559.
236. Quan N., Sundar S.K., Weiss J.M. Induction of interleukin-1 in various brain regions after peripheral and central injections of lipopolysaccharide. J. Neuroimmunol. 1994, 49:125-134.
237. Radic Z., KirchhoffP.D., Quinn D.M., McCammon J.A., Taylor P. Electrostatic influence on the kinetics of ligand binding to acetylcholinesterase. Distinctions between active center ligands and fasciculin. J. Biol. Chem. 1997, 272:23265-23277.
238. Randell E.W., Mathews M.S., Zhang H., Seraj J.S., Sun G. Relationship between serum butyrylcholinesterase and the metabolic syndrome. Clin. Biochem. 2005, 38:799-805.
239. Raveh L., Grunwald J., Marcus D., Papier Y., Cohen E., Ashani Y. Human butyrylcholinesterase as a general prophylactic antidote for nerve agent toxicity. In vitro and in vivo quantitative characterization. Biochem. Pharmacol. 1993, 45:2465-2474.
240. Raveh L., Grauer E., Grunwald J., Cohen E., Ashani Y. The stoichiometry of protection against soman and VX toxicity in monkeys pretreated with human butyrylcholinesterase. Toxicol. Appl. Pharmacol. 1997, 145:43-53.
241. Ray D.E., Richards P.G. The potential for toxic effects of chronic, low-dose exposure to organophosphates. Toxicol. Lett. 2001, 120:343-351.
242. Reddy S.T., Wadleigh D.J., Grijalva V., Ng C., Hama S., Gangopadhyay A., Shih D.M., Lusis A.J., Navab M., Fogelman A.M. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler. Thromb. Vasc. Biol. 2001, 21:542-547.
243. Rees T.M., Brimijoin S. The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease. Drugs Today (Barc.) 2003, 39:75-83.
244. Rees T., Hammond P.I., Soreq H., Younkin S., Brimijoin S. Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex. Neurobiol. Aging 2003, 24:777-787.
245. Rees T.M., Berson A., Sklan E.H., Younkin L., Younkin S., Brimijoin S., Soreq H. Memory deficits correlating with acetylcholinesterase splice shift and amyloid burden in doubly transgenic mice. Curr. Alzheimer Res. 2005, 2:291-300.
246. Ringman J.M., Cummings J.L. Current and emerging pharmacological treatment options for dementia. Behav. Neurol. 2006, 17:5-16.
247. Ropper A.H., Brown R.H. Adams and Victor's Principles of Neurology 2005, McGraw-Hill, New York.
248. Rosenblat M., Gaidukov L., Khersonsky O., Vaya J., Oren R., Tawfik D.S., Aviram M. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J. Biol. Chem. 2006, 281:7657-7665.
249. Rosenstock L., Keifer M., Daniell W.E., McConnell R., Claypoole K. Chronic central nervous system effects of acute organophosphate pesticide intoxication. The Pesticide Health Effects Study Group. Lancet 1991, 338:223-227.
250. Rossi S.G., Dickerson I.M., Rotundo R.L. Localization of the calcitonin gene-related peptide receptor complex at the vertebrate neuromuscular junction and its role in regulating acetylcholinesterase expression. J. Biol. Chem. 2003, 278:24994-25000.
251. Rotundo R.L. Nucleus-specific translation and assembly of acetylcholinesterase in multinucleated muscle cells. J. Cell. Biol. 1990, 110:715-719.
252. Saez-Valero J., Fodero L.R., Sjogren M., Andreasen N., Amici S., Gallai V., Vanderstichele H., Vanmechelen E., Parnetti L., Blennow K., Small D.H. Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease. J. Neurosci. Res. 2003, 72:520-526.
253. Salmon A., Erb C., Meshorer E., Ginzberg D., Adani Y., Rabinovitz I., Amitai G., Soreq H. Muscarinic modulations of neuronal anticholinesterase responses. Chem. Biol. Interact. 2005, 157-8:105-113.
254. Salmon A.Y., Goren Z., Avissar Y., Soreq H. Human erythrocyte but not brain acetylcholinesterase hydrolyses heroin to morphine. Clin. Exp. Pharmacol. Physiol. 1999, 26:596-600.
255. Sanes J.R. Genetic analysis of postsynaptic differentiation at the vertebrate neuromuscular junction. Curr. Opin. Neurobiol. 1997, 7:93-100.
256. Sapolsky R.M., Romero L.M., Munck A.U. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr. Rev. 2000, 21:55-89.
257. Saxena, A., Maxwell, D.M., Quinn, D.M., Radic, Z., Taylor, P., Doctor, B.P. (1997a). Mutant acetylcholinesterases as potential detoxification agents for organophosphate poisoning. Biochem. Pharmacol.54: 269-74.
258. Saxena, A., Raveh, L., Ashani, Y., Doctor, B.P. (1997b). Structure of glycan moieties responsible for the extended circulatory life time of fetal bovine serum acetylcholinesterase and equine serum butyrylcholinesterase. Biochemistry36: 7481-9.
259. Schober A., Minichiello L., Keller M., Huber K., Layer P.G., Roig-Lopez J.L., Garcia-Arraras J.E., Klein R., Unsicker K. Reduced acetylcholinesterase (AChE) activity in adrenal medulla and loss of sympathetic preganglionic neurons in TrkA-deficient, but not TrkB-deficient, mice. J. Neurosci. 1997, 17:891-903.
260. Schonbeck S., Chrestel S., Hohlfeld R. Myasthenia gravis: prototype of the antireceptor autoimmune diseases. Int. Rev. Neurobiol. 1990, 32:175-200.
261. Schumacher M., Camp S., Maulet Y., Newton M., MacPhee-Quigley K., Taylor S.S., Friedmann T., Taylor P. Primary structure of Torpedo californica acetylcholinesterase deduced from its cDNA sequence. Nature 1986, 319:407-409.
262. Schwarz M., Glick D., Loewenstein Y., Soreq H. Engineering of human cholinesterases explains and predicts diverse consequences of administration of various drugs and poisons. Pharmacol. Ther. 1995, 67:283-322.
263. Seidman S., Sternfeld M., Ben Aziz-Aloya R., Timberg R., Kaufer-Nachum D., Soreq H. Synaptic and epidermal accumulations of human acetylcholinesterase are encoded by alternative 30-terminal exons. Mol. Cell. Biol. 1995, 15:2993-3002.
264. Serajee F.J., Nabi R., Zhong H., Huq M. Polymorphisms in xenobiotic metabolism genes and autism. J. Child Neurol. 2004, 19:413-417.
265. Shapira M., Tur-Kaspa I., Bosgraaf L., Livni N., Grant A.D., Grisaru D., Korner M., Ebstein R.P., Soreq H. A transcription-activating polymorphism in the ACHE promoter associated with acute sensitivity to anti-acetylcholinesterases. Hum. Mol. Genet. 2000, 9:1273-1281.
266. Shih D.M., Gu L., Xia Y.R., Navab M., Li W.F., Hama S., Castellani L.W., Furlong C.E., Costa L.G., Fogelman A.M., Lusis A.J. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998, 394:284-287.
267. Shih D.M., Xia Y.R., Wang X.P., Miller E., Castellani L.W., Subbanagounder G., Cheroutre H., Faull K.F., Berliner J.A., Witztum J.L., Lusis A.J. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J. Biol. Chem. 2000, 275:17527-17535.
268. Shohami E., Kaufer D., Chen Y., Seidman S., Cohen O., Ginzberg D., Melamed-Book N., Yirmiya R., Soreq H. Antisense prevention of neuronal damages following head injury in mice. J. Mol. Med. 2000, 78:228-236.
269. Sijmons P.C., Dekker B.M., Schrammeijer B., Verwoerd T.C., Van den Elzen P.J., Hoekema A. Production of correctly processed human serum albumin in transgenic plants. Biotechnology (NY) 1990, 8:217-221.
270. Silman I., Sussman J.L. Acetylcholinesterase: "classical' and "non-classical' functions and pharmacology. Curr. Opin. Pharmacol. 2005, 5:293-302.
271. Silman I., di Giamberardino L., Lyles L., Couraud J.Y., Barnard E.A. Parallel regulation of acetylcholinesterase and pseudocholinesterase in normal, denervated and dystrophic chicken skeletal muscle. Nature 1979, 280:160-162.
272. Silveyra M.X., Garcia-Ayllon M.S., Calero M., Saez-Valero J. Altered glycosylation of acetylcholinesterase in the Creutzfeldt-Jakob cerebrospinal fluid. J. Mol. Neurosci. 2006, 30:65-66.
273. Simone C., Derewlany L.O., Oskamp M., Johnson D., Knie B., Koren G. Acetylcholinesterase and butyrylcholinesterase activity in the human term placenta: implications for fetal cocaine exposure. J. Lab. Clin. Med. 1994, 123:400-406.
274. Singh A.K., Jiang Y. Lipopolysaccharide (LPS) induced activation of the immune system in control rats and rats chronically exposed to a low level of the organothiophosphate insecticide, acephate. Toxicol. Ind. Health 2003, 19:93-108.
275. Sklan E.H., Lowenthal A., Korner M., Ritov Y., Landers D.M., Rankinen T., Bouchard C., Leon A.S., Rice T., Rao D.C., Wilmore J.H., Skinner J.S., Soreq H. Acetylcholinesterase/paraoxonase genotype and expression predict anxiety scores in health, risk factors, exercise training, and genetics study. Proc. Natl Acad. Sci. USA 2004, 101:5512-5517.
276. Sklan E.H., Podoly E., Soreq H. RACK1 has the nerve to act: structure meets function in the nervous system. Prog. Neurobiol. 2006, 78:117-134.
277. Small D.H., Reed G., Whitefield B., Nurcombe V. Cholinergic regulation of neurite outgrowth from isolated chick sympathetic neurons in culture. J. Neurosci. 1995, 15:144-151.
278. Small D.H., Michaelson S., Sberna G. Non-classical actions of cholinesterases: role in cellular differentiation, tumorigenesis and Alzheimer's disease. Neurochem. Int. 1996, 28:453-483.
279. Sogorb M.A., Vilanova E., Carrera V. Future applications of phosphotriesterases in the prophylaxis and treatment of organophosporus insecticide and nerve agent poisonings. Toxicol. Lett. 2004, 151:219-233.
280. Sons M.S., Busche N., Strenzke N., Moser T., Ernsberger U., Mooren F.C., Zhang W., Ahmad M., Steffens H., Schomburg E.D., Plomp J.J., Missler M. Alpha-neurexins are required for efficient transmitter release and synaptic homeostasis at the mouse neuromuscular junction. Neuroscience 2006, 138:433-446.
281. Soreq H., Seidman S. Acetylcholinesterase -new roles for an old actor. Nat. Rev. Neurosci. 2001, 2:294-302.
282. Soreq H., Ben-Aziz R., Prody C.A., Seidman S., Gnatt A., Neville L., Lieman-Hurwitz J., Lev-Lehman E., Ginzberg D., Lipidot-Lifson Y., Zakut H. Molecular cloning and construction of the coding region for human acetylcholinesterase reveals a G+C-rich attenuating structure. Proc. Natl Acad. Sci. USA 1990, 87:9688-9692.
283. Stamm S., Ben-Ari S., Rafalska I., Tang Y., Zhang Z., Toiber D., Thanaraj T.A., Soreq H. Function of alternative splicing. Gene 2005, 344:1-20.
284. Sternfeld M., Ming G., Song H., Sela K., Timberg R., Poo M., Soreq H. Acetylcholinesterase enhances neurite growth and synapse development through alternative contributions of its hydrolytic capacity, core protein, and variable C termini. J. Neurosci. 1998, 18:1240-1249.
285. Sternfeld M., Shoham S., Klein O., Flores-Flores C., Evron T., Idelson G.H., Kitsberg D., Patrick J.W., Soreq H. Excess "read-through' acetylcholinesterase attenuates but the "synaptic' variant intensifies neurodeterioration correlates. Proc. Natl Acad. Sci. USA 2000, 97:8647-8652.
286. Sussman J.L., Harel M., Frolow F., Oefner C., Goldman A., Toker L., Silman I. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 1991, 253:872-879.
287. Svensson I., Waara L., Johansson L., Bucht A., Cassel G. Soman-induced interleukin-1 beta mRNA and protein in rat brain. Neurotoxicology 2001, 22:355-362.
288. Tacke R., Manley J.L. Determinants of SR protein specificity. Curr. Opin. Cell. Biol. 1999, 11:358-362.
289. Taylor M.C., Le Couteur D.G., Mellick G.D., Board P.G. Paraoxonase polymorphisms, pesticide exposure and Parkinson's disease in a Caucasian population. J. Neural Transm. 2000, 107:979-983.
290. Taylor P. Anticholinesterase agents. Goodman and Gilman's The Pharmacological Basis of Therapeutics 1996, 161-176. McGraw-Hill, New York. J.G. Hardman, L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Gilman (Eds.).
291. Toiber D., Soreq H. Cellular stress reactions as putative cholinergic links in Alzheimer's disease. Neurochem. Res. 2005, 30:909-919.
292. Tomkins O., Kaufer D., Shelef I., Hertzanu Y., Richenthal E., Soreq H., Friedman A. Frequent blood-brain barrier disruption in the cerebral cortex. Cell. Mol. Neurobiol. 2001, 21:675-691.
293. Tracey K.J. The inflammatory reflex. Nature 2002, 420:853-859.
294. Tracey K.J., Czura C.J., Ivanova S. Mind over immunity. FASEB J. 2001, 15:1575-1576.
295. Turrin N.P., Gayle D., Ilyin S.E., Flynn M.C., Langhans W., Schwartz G.J., Plata-Salaman C.R. Pro-inflammatory and anti-inflammatory cytokine mRNA induction in the periphery and brain following intraperitoneal administration of bacterial lipopolysaccharide. Brain Res. Bull. 2001, 54:443-453.
296. Tyagi E., Agrawal R., Nath C., Shukla R. Effect of anti-dementia drugs on LPS induced neuroinflammation in mice. Life Sci. 2007, 80:1977-1983.
297. Van Himbergen T.M., Van Tits L.J., Roest M., Stalenhoef A.F. The story of PON1: how an organophosphate-hydrolysing enzyme is becoming a player in cardiovascular medicine. Neth. J. Med. 2006, 64:34-38.
298. Van Westerloo D.J., Giebelen I.A., Florquin S., Daalhuisen J., Bruno M.J., de Vos A.F., Tracey K.J., Van der Poll T. The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis. J. Infect. Dis. 2005, 191:2138-2148.
299. Velan B., Kronman C., Grosfeld H., Leitner M., Gozes Y., Flashner Y., Sery T., Cohen S., Ben-Aziz R., Seidman S., Shafferman A., Soreq H. Recombinant human acetylcholinesterase is secreted from transiently transfected 293 cells as a soluble globular enzyme. Cell. Mol. Neurobiol. 1991, 11:143-156.
300. Vermij P. USDA approves the first plant-based vaccine. Mol. Biol. Evol. 2006, 24:234.
301. Wang H., Yu M., Ochani M., Amella C.A., Tanovic M., Susarla S., Li J.H., Yang H., Ulloa L., Al-Abed Y., Czura C.J., Tracey K.J. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003, 421:384-388.
302. Wang H.Y., Xu X., Ding J.H., Bermingham J.R., Fu X.D. SC35 plays a role in T cell development and alternative splicing of CD45. Mol. Cell. 2001, 7:331-342.
303. Weinbroum A.A. Pathophysiological and clinical aspects of combat anticholinesterase poisoning. Br. Med. Bull. 2005, 72:119-133.
304. Xie H.Q., Choi R.C., Leung K.W., Siow N.L., Kong L.W., Lau F.T., Peng H.B., Tsim K.W. Regulation of a transcript encoding the proline-rich membrane anchor of globular muscle acetylcholinesterase. The suppressive roles of myogenesis and innervating nerves. J. Biol. Chem. 2007, 282:11765-11775.
305. Yanagisawa N., Morita H., Nakajima T. Sarin experiences in Japan: acute toxicity and long-term effects. J. Neurol. Sci. 2006, 249:76-85.
306. Yeung D.T., Josse D., Nicholson J.D., Khanal A., McAndrew C.W., Bahnson B.J., Lenz D.E., Cerasoli D.M. Structure/function analyses of human serum paraoxonase (HuPON1) mutants designed from a DFPase-like homology model. Biochim. Biophys. Acta 2004, 1702:67-77.
307. Yeung D.T., Lenz D.E., Cerasoli D.M. Analysis of active-site amino-acid residues of human serum paraoxonase using competitive substrates. FEBS J. 2005, 272:2225-2230.
308. Zimmerman G., Soreq H. "Readthrough' acetylcholinesterase: a multifaceted inducer of stress reactions. J. Mol. Neurosci. 2006, 30:197-200.